How to bolster the antifungal pipeline: Few drugs are coming to market, but opportunities for drug development exist

Science

Volumn 347, Issue 6229, 2015, Pages 1414-1416

  Denning, David W ^a,b   Bromley, Michael J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; AUREOBASIDIN A; CYCLOSPORIN; ECHINOCANDIN; EFUNGUMAB; ERGOSTEROL; FLUCONAZOLE; GM 237354; GRISEOFULVIN; ICOFUNGIPEN; ISAVUCONAZOLE; NIKKOMYCIN Z; PYRROLE DERIVATIVE; TACROLIMUS; TAVABOROLE; THERMOZYMOCIDIN; VORICONAZOLE;

ANTIMICROBIAL ACTIVITY; DRUG DEVELOPMENT; HEALTH CARE; MARKET CONDITIONS;

ASPERGILLUS; CANDIDA; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; DRUG TREATMENT FAILURE; HUMAN; INVASIVE ASPERGILLOSIS; LIVER FUNCTION TEST; MYCOSIS; PNEUMOCYSTIS; PRIORITY JOURNAL; REVIEW; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASTHMA; CYSTIC FIBROSIS; DRUG DESIGN; DRUG RESISTANCE, FUNGAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VORICONAZOLE;

EID: 84926058258     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaa6097     Document Type: Review

References (18)

1. T. Vos et al., Lancet 380, 2163 (2012).
2. G. D. Brown et al., Sci. Transl. Med. 4, 165rv13 (2012).
3. www.gaffi.org
4. S. Perkhofer et al., Int. J. Antimicrob. Agents 36, 531 (2010).
5. J. M. Valdez et al., Clin. Infect. Dis. 52, 726 (2011).
6. D. W. Denning et al., Clin. Infect. Dis. 34, 563 (2002).
7. H. R. Ashbee et al., J. Antimicrob. Chemother. 69, 1162 (2014).
8. R. Herbrecht et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group, N. Engl. J. Med. 347, 408 (2002).
9. M. Slavin et al., Clin. Microbiol. Infect. 10.1016/j.cmi.2014.12.021 (2015).
10. E. Snelders et al., PLOS ONE 7, e31801 (2012).
11. European Crop Protection Association, Assessment of the Economic Importance of Azoles in European Agriculture: Wheat Case Study; www.ecpa.eu/article/agriculture-today/assessment-economic-importance-azoles-europeanagriculture-wheat-case-stud.
12. Investigational new drug (IND)-enabling studies: biafungin (Cidara), VT-1129 (Viament); phase I: F901318 (F2G Ltd.), nickkomycin Z (Valley Fever Solutions); phase II: SCY-078 (Scynexis); phase III: isavuconazole (Basilea Pharmaceutica Ltd.).
13. T. Roemer, C. Boone, Nat. Chem. Biol. 9, 222 (2013).
14. D. W. Denning et al., Clin. Transl. Allergy 4, 14 (2014).
15. J. Cadranel et al., Eur. J. Clin. Microbiol. Infect. Dis. 31, 3231 (2012).
16. www.mrc.ac.uk/documents/pdf/fungal-diseaseresearch-workshop-report
17. J. H. Rex et al., Lancet Infect. Dis. 13, 269 (2013).
18. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM420235.pdf